azacitidine + fulvestrant

The combination of azacitidine (or its oral form CC-486) with fulvestrant is an investigational therapy for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer in postmenopausal women who have progressed on aromatase inhibitor therapy. Azacitidine is a hypomethylating agent that acts as an epigenetic modulator, while fulvestrant is a selective estrogen receptor degrader. The rationale for combining these agents is to leverage the epigenetic modifying effects of azacitidine to potentially restore sensitivity to endocrine therapy and improve outcomes[1][4].

Other names

CC-486 + fulvestrantoral azacitidine + fulvestrant